Drug intelligence / Profile preview

AD-236

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-236 is an investigational fixed-dose combination drug candidate being developed by Addpharma, a subsidiary of Yuhan, for the treatment of hyperlipidemia and type 2 diabetes mellitus. The formulation consists of two components, designated as AD-236A and AD-236B, whose specific active ingredients have not been publicly disclosed. In 2026, Addpharma initiated a Phase 1 clinical trial (NCT07730567) to evaluate the pharmacokinetic interactions and safety of AD-236A and AD-236B in healthy adult volunteers.

Other names: rosuvastatin/metformin fixed-dose combination

Targets

ND1 (Mitochondrial electron transport chain complex I)AMPK (Adenosine monophosphate–activated protein kinase)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on AD-236.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-236.

Explore the full profile